CD2-HM12NB-100μg / 询价
CD2-HM12NB-100μgx5 / 询价
CD2-HM12NB-100μgx10 / 询价
Biotinylated Human CD20/MS4A1 Nanodisc
Our Styrene-Maleic Anhydride(SMA) nanodisc platform delivers multi-pass transmembrane proteins exactly as they exist in the HEK293 cell membrane following recombinant expression— preserving their endogenous lipid environment and correct conformational states. Isolated directly from HEK293 cells via a gentle, detergent-free process, the multi-pass membrane proteins are subsequently encapsulated by SMA to ensure their stability. These uniform soluble nanoparticles eliminate extraction interferences while maintaining biological activity. Ensuring consistent performance from lot to lot, our nanodiscs provide the reliability and biological relevance essential for antibody screening and functional characterization in therapeutic antibody drug discovery and development, as assessed by SPR, BLI, ELISA, and other standard platforms.
❖ Correct structure & conformation
❖ Functional relevance ensured
❖ His-tag & biotinylation tag available
❖ Antibody screening
❖ Functional characterization(Molecular Level)
❖ Assay: SPR, BLI, ELISA
Recombinant Biotinylated Human CD20/MS4A1 Nanodisc is expressed from HEK293 with His tag at the C-terminus.It contains Met1-Pro297 [Accession | P11836-1].
The protein has a predicted MW of 46.0 kDa.
Less than 1 EU per μg by the LAL method.
Supplied as 0.22 μm filtered solution in PBS, 200mM L-arginine (pH 7.4). Notice: Not recommended for flow cytometry in mammalian cells.
Valid for 6 months from date of receipt when stored at -80°C.
Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
B-lymphocyte antigen CD20 or CD20 is an activated-glycosylated phosphoprotein expressed on the surface of all B-cells beginning at the pro-B phase (CD45R , CD117) and progressively increasing in concentration until maturity.CD20 is the target of the monoclonal antibodies rituximab, ocrelizumab, obinutuzumab, ofatumumab, ibritumomab tiuxetan, tositumomab, and ublituximab, which are all active agents in the treatment of all B cell lymphomas, leukemias, and B cell-mediated autoimmune diseases.
MS4A1; CD20; MS4A-1; B1; Bp35; CD20 receptor; CD20S7; CVID5; LEU-16; Ly-44; MS4A2; S7;LEU16; Ly44
(1)Ma D , Mcdevitt M R , Barendswaard E , et al. Radioimmunotherapy for model B cell malignancies using 90Y-labeled anti-CD19 and anti-CD20 monoclonal antibodies[J]. Leukemia, 2002, 16(1):60-66.
(2)Jager U , Fridrik M , Zeitlinger M , et al. Rituximab serum concentrations during immuno-chemotherapy of follicular lymphoma correlate with patient gender, bone marrow infiltration and clinical response[J]. Haematologica, 2012, 97(9):1431-1438.
